Actinogen Limited announced the appointment of a powerhouse team of globally recognised leaders in Alzheimer's disease research to its
Xanamem Advisory Board - Professor Craig Ritchie from Edinburgh UK, Professor Colin Masters from Melbourne Australia and Professor Jeff Cummings from the Cleveland Clinic USA. This Advisory Board has particular expertise in the early diagnosis and treatment of Alzheimer's disease and will help Actinogen Medical shape and drive the development of its new lead research drug, Xanamem. The Advisory Board will be chaired by Professor Craig Ritchie, Professor of Psychiatry of Ageing at the University of Edinburgh. Professor Ritchie is a leading authority on clinical trials in dementia and has been senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. He has extensive knowledge of the industry, having sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer's disease. Professor Colin Masters is currently the Executive Director of the Mental Health Research Institute, and a Laureate Professor at the University of Melbourne. He is also the Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital. Professor Jeff Cummings is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.